10:17:17 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



Emerald Health prospectus offering

2017-05-04 16:44 ET - Prospectus Approved

Effective May 3, 2017, the company's short form base shelf prospectus dated Jan. 25, 2017, and prospectus supplement dated April 12, 2017, were filed with and accepted by the TSX Venture Exchange, and filed with and receipted by the securities commissions of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Newfoundland and Labrador, New Brunswick, Prince Edward Island, and Nova Scotia, pursuant to the provisions of the securities acts of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Newfoundland and Labrador, New Brunswick, Prince Edward Island, and Nova Scotia.

The TSX Venture Exchange has been advised that closing occurred on April 20, 2017, and April 21, 2017, for gross proceeds of $27,123,423.

Agents:  Eight Capital

Offering:  13.17 million units, 1,465,100 common shares and 987,750 warrants (Each unit consists of one share and one-half of one warrant. Each whole warrant is exercisable into one common share of the company at an exercise price of $2.60 per warrant share for up to 24 months following closing.)

Unit prices:  $1.85 per unit, $1.755 per share and 19 cents per warrant

Warrant exercise price/term:  $2.60 per share to April 20, 2019

Agent's options:  439,053 non-transferable compensation options exercisable to purchase one unit at $1.85 per unit to April 20, 2019 (Each agent's unit has the same terms as the offering units.)

For further information, please see the company's news releases dated April 10, 2017, April 11, 2017, April 20, 2017, and April 21, 2017.

© 2024 Canjex Publishing Ltd. All rights reserved.